Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2104-2107

  Horwich, A ^a   Dearnaley, D P ^a   Sohaib, A ^b   Pennert, K ^b   Huddart, R A ^a  

^a The Institute of Cancer Research and Urological Oncology Unit   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Carboplatin; Germ cell tumour; Radiotherapy; Seminoma

Indexed keywords

CARBOPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER FATIGUE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DOSIMETRY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RADIATION INJURY; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEMINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME;

CARBOPLATIN; GERM CELL TUMOUR; RADIOTHERAPY; SEMINOMA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; SEMINOMA; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 84881218346     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt148     Document Type: Article

References (29)

1. Chung PW, Gospodarowicz MK, Panzarella Tet al.Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 2004; 45(6): 754-759; discussion 759-60.
2. Classen J, Schmidberger H, Meisner Cet al.Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003; 21(6): 1101-1106.
3. Patterson H, Norman AR, Mitra SSet al.Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol 2001; 59(1): 5-11.
4. Detti B, Livi L, Scoccianti Set al.Management of stage II testicular seminoma over a period of 40 years. Urol Oncol 2009; 27(5): 534-538.
5. Zagars GK, Pollack A. Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 2001; 51(3): 643-649.
6. van den Belt-Dusebout AW, de Wit R, Gietema JAet al.Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25(28): 4370-4378.
7. Travis LB, Fosså SD, Schonfeld SJet al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97(18): 1354-1365.
8. Oliver RT, Mead GM, Rustin GJet al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011; 29(8): 957-962.
9. van As NJ, Gilbert DC, Money-Kyrle Jet al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 2008; 98(12): 1894-1902.
10. Newcombe RG. 'Two-sided confidence intervals for the single proportion: comparison of seven methods'. Stat Med 1998; 17: 857-872.
11. Gilbert DC, Van as NJ, Beesley Set al. Treating IIA/B seminoma with combination carboplatin and radiotherapy. J Clin Oncol 2009; 27(12): 2101-2102.
12. Zwahlen DR, Martin JM, Millar JLet al. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2008; 70(3): 853-858.
13. Kollmannsberger C, Hartmann JT, Kanz Let al. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 1999; 83(6): 860-863.
14. Swerdlow AJ, Higgins CD, Smith Pet al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011; 29(31): 4096-4104.
15. Powles T, Robinson D, Shamash Jet al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008; 19(3): 443-447.
16. Loehrer PJ, Sr, Birch R, Williams SDet al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987; 5(8): 1212-1220.
17. Mencel PJ, Motzer RJ, Mazumdar Met al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994; 12(1): 120-126.
18. Fosså SD, Oliver RT, Stenning SPet al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 1997; 33(9): 1380-1387.
19. Horwich A, Oliver RT, Wilkinson PMet al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer 2000; 83(12): 1623-1629.
20. Clemm C, Bokemeyer C, Gerl Aet al. Randomized trial comparing cisplatin/ etoposide/ifosfamide with carboplatin monochemotherapy in patients with advanced metastatic seminoma. Proc Am Soc Clin Oncol 2000; 19: 328. (abstract 1283).
21. Krege S, Boergermann C, Baschek Ret al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 2006; 17(2): 276-280.
22. Garcia-del-Muro X, Maroto P, Gumà Jet al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008; 26(33): 5416-5421.
23. Domont J, Massard C, Patrikidou Aet al. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol 2011 June 10 [epub ahead of print], http://www.urologiconcology.org/ article/S1078-1439(11)00133-5/abstract.
24. Schmoll HJ, Jordan K, Huddart Ret al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v140-v146.
25. Wood L, Kollmannsberger C, Jewett Met al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 2010; 4(2): e19-e38.
26. Warde P, Huddart R, Bolton Det al. Management of localized seminoma, stage III: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology 2011; 78(4 Suppl): S435-S443.
27. Albers P, Albrecht W, Algaba Fet al. update. European Association of Urology. Actas Urol Esp 2011; 36(3): 127-145.
28. Horwich A, Dearnaley DP, Duchesne GMet al. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol 1989; 7: 1150-1156.
29. Paly JJ, Efstathiou JA, Hedgier SSet al. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Radiother Oncol 2013; 106: 64-68.